Phuc Tran

Undergraduate Researcher

University of Arkansas for Medical Sciences

faculty

6 h-index 13 pubs 141 cited

Is this your profile? Verify and claim your profile

Biography and Research Information

OverviewAI-generated summary

Phuc Tran's research focuses on the discovery and development of novel therapeutic agents, particularly in the field of oncology. Their work has explored various molecular targets and strategies for cancer treatment, including inhibitors of specific kinases and modulators of protein degradation pathways. Publications detail the identification of compounds that inhibit FLT3-ITD, a mutation associated with certain leukemias, and selective aurora kinase B inhibitors with potential for oral administration. Additionally, Tran has investigated bifunctional inhibitors targeting HDACs and BRD4 for virus-associated lymphomas and explored TGFβR1 inhibitors for immuno-oncology applications. The research also extends to optimizing drug delivery methods, such as evaluating the efficiency of oligonucleotide delivery with lipid conjugation.

Metrics

  • h-index: 6
  • Publications: 13
  • Citations: 141

Selected Publications

  • Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor (2025) DOI
  • CD36-mediated endocytosis of proteolysis-targeting chimeras (2025) DOI
  • An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L (2023) DOI
  • Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas (2023) DOI
  • Delivery of Oligonucleotides: Efficiency with Lipid Conjugation and Clinical Outcome (2022) DOI
  • 3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O’PROTAC (2022) DOI
  • Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose (2022) DOI
  • Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology (2021) DOI
  • Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors (2021) DOI

Collaborators

Researchers in the database who share publications

Similar Researchers

Based on overlapping research topics